CLINICAL TRIALS PROFILE FOR SURUFATINIB
✉ Email this page to a colleague
Clinical Trials for Surufatinib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02267967 ↗ | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | Completed | Hutchison Medipharma Limited | Phase 1 | a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors |
| NCT02549937 ↗ | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | Recruiting | Hutchison Medipharma Limited | Phase 1/Phase 2 | Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D). Primary Objective Dose Expansion: To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs), and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD. Secondary Objective: To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients with advanced solid tumors. |
| NCT02588170 ↗ | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | Active, not recruiting | Hutchison Medipharma Limited | Phase 3 | A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine tumors. |
| NCT02589821 ↗ | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | Active, not recruiting | Hutchison Medipharma Limited | Phase 3 | A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors. |
| NCT02614495 ↗ | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | Completed | Hutchison Medipharma Limited | Phase 2 | A multi-center , opened, Phase II study to assess the efficacy and safety of Sulfatinib 300 mg Sulfatinib in advanced Medullary Thyroid Carcinoma ( MTC) and iodine-refractory differentiated thyroid carcinoma (DTC). |
| NCT02966821 ↗ | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | Completed | Hutchison Medipharma Limited | Phase 2 | A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma |
| NCT03483259 ↗ | To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers | Completed | Hutchison Medipharma Limited | Phase 1 | This is a single-center, randomized, open, single-dose, three-cycle cross-design study, which will be only enrolled Chinese male healthy volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Surufatinib
Condition Name
Clinical Trial Locations for Surufatinib
Trials by Country
Clinical Trial Progress for Surufatinib
Clinical Trial Phase
Clinical Trial Sponsors for Surufatinib
Sponsor Name
